发明名称 TRPM-2 antisense therapy
摘要 It has been determined that antisense therapy which reduces the expression of TRPM- 2 provides therapeutic benefits in the treatment of cancer, particularly prostate and renal cell cancers. Addition of antisense TRPM- 2 ODN to prostatic tumor cells in vivo is effective for delaying the onset of androgen independence, thus prostate cancer can be treated by initiating androgen-withdrawal to induce apoptotic cell death of prostatic tumor cells in an individual, and administering a composition effective to inhibit expression of TRPM- 2 by the tumor cells. Combined use of antisense TRPM- 2 and taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer and in human Renal cell cancer. Radiation sensitivity is also enhanced when cells expressing TRPM- 2 are treated with antisense TRPM- 2 ODN. Thus, the antisense TRPM- 2 ODNs can be used to enhance hormone sensitivity, chemosensitivity and radiation sensitivity of a variety of cancer types in which expression of TRPM- 2 has been observed.
申请公布号 US7368436(B2) 申请公布日期 2008.05.06
申请号 US20010944326 申请日期 2001.08.30
申请人 THE UNIVERSITY OF BRITISH COLUMBIA 发明人 GLEAVE MARTIN;RENNIE PAUL S.;MIYAKE HIDEAKI;NELSON COLLEEN
分类号 A61K31/70;C12N15/09;A61K31/00;A61K31/136;A61K31/337;A61K31/66;A61K31/704;A61K31/7105;A61K38/00;A61K41/00;A61K45/06;A61K48/00;A61P5/24;A61P5/28;A61P35/00;A61P43/00;C07H21/00;C07H21/04;C07K14/775;C12N15/113 主分类号 A61K31/70
代理机构 代理人
主权项
地址
您可能感兴趣的专利